The role of B7 family molecules in hematologic malignancy
about
Immunotherapy in Chronic Lymphocytic Leukaemia (CLL)Catching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas?Lymphoma: immune evasion strategiesPD-1, PD-L1 and PD-L2 Gene Expression on T-Cells and Natural Killer Cells Declines in Conjunction with a Reduction in PD-1 Protein during the Intensive Phase of Tuberculosis TreatmentThe development of endometrial hyperplasia in aged PD-1-deficient female mice.Role of programmed death ligands in effective T-cell interactions in extranodal natural killer/T-cell lymphomaB7-H6 expression in non-small cell lung cancers.New strategies in acute myelogenous leukemia: leukemogenesis and personalized medicine.Looking in the Porphyromonas gingivalis cabinet of curiosities: the microbium, the host and cancer associationEnhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression.B7-H4 expression is associated with tumor progression and prognosis in patients with osteosarcoma.PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemiaHigh PD-L1 Expression Correlates with Metastasis and Poor Prognosis in Oral Squamous Cell Carcinoma.Haematological malignancies: at the forefront of immunotherapeutic innovation.Prognostic role of high B7-H4 expression in patients with solid tumors: a meta-analysis.Inhibitory receptors as targets for cancer immunotherapyEffect of Chronic Uremia on the Cell Surface Expression of B7 Family Costimulatory Molecules in an HLA-A2 Transgenic Mouse Model of Chronic Kidney Disease.Cancer immunotherapy: Strategies for personalization and combinatorial approaches.Immune Regulation by Self-Recognition: Novel Possibilities for Anticancer Immunotherapy.Clinical significance of B7-H6 protein expression in astrocytoma.Dose-enhanced combined priming regimens for refractory acute myeloid leukemia and middle-and-high-risk myelodysplastic syndrome: a single-center, retrospective cohort study.Comprehensive molecular profiling of the B7 family of immune-regulatory ligands in breast cancer.B7-H3 protein expression in acute myeloid leukemia.Vitamin D receptor and CD86 expression in the skin of vitamin D-deficient swine.Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity.Two immune faces of pancreatic adenocarcinoma: possible implication for immunotherapy.The targeting of immunosuppressive mechanisms in hematological malignancies.Tumor-associated macrophages: from mechanisms to therapy.Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia.PD-L1-specific T cells.Cutaneous T cell lymphoma expresses immunosuppressive CD80 (B7-1) cell surface protein in a STAT5-dependent manner.Anti-regulatory T cells.The next generation of therapeutics for chronic kidney diseaseLenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma.Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells.PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.Tumor-associated macrophages: implications in cancer immunotherapy.The Role of Dendritic Cell Maturation in the Induction of Insulin-Dependent Diabetes Mellitus.Multiplexing of receptor occupancy measurements for pharmacodynamic biomarker assessment of biopharmaceuticals.Identification of 14-dehydroergosterol as a novel anti-inflammatory compound inducing tolerogenic dendritic cells
P2860
Q26768154-EABC4EC4-B301-4DB6-8623-AE20D8A87073Q28076071-5457B3D7-1C1C-4E45-9500-9AC600E7FBE1Q28080705-8763BAE9-B1BB-4732-A07E-294C340766D2Q28547901-3933A4A4-9FE6-410E-B604-D91610F93C95Q33791391-44377940-84BD-4B83-BB13-817705344547Q34141476-06E0CB4C-0697-4BF2-A49F-7B9B85C09E8FQ34501622-C80EF847-F005-4BF4-B342-CA644305A41AQ34715598-C05C9C1A-5E37-4059-9840-A2A51210BA37Q35088939-5284FF59-B2D0-4B9A-9F42-385A5879952BQ35399334-FBC7E7C3-557D-43EC-AF29-F0E0B17956B7Q35543730-4CEA7E6D-3DC4-451B-8810-663AA912B6B4Q35836860-66B8ED7E-43B3-45FD-8548-06DB959AC108Q35839942-B2182D20-A9BA-4023-8220-56730DE5047CQ35880618-04A28118-2E2B-4671-9F36-A979D94E95CBQ35983676-F253A2E1-DF14-4E67-B077-C070808DC858Q35995373-105FC4C5-D18B-4491-AB26-DEDE59165976Q35996468-4F6DF7C6-FED7-44E2-B13B-2426A41CABDCQ36387028-E76A68E1-861D-43A5-ABED-DF637B18D921Q36813010-E9BDD30B-CC8F-4623-BB5E-5563E88454B4Q36982231-516090FE-F39C-42D9-8090-FE92C78128C4Q37036452-2AD37B43-10AD-41C0-86BC-07A7F928019AQ37224577-3053C933-3C20-4836-8829-41E5F9C01898Q37441516-B56D67F7-5AFB-4397-8485-E835244AEBB9Q37598688-457E2ED0-6DE3-421B-901C-5608D9B9F4EEQ38108353-4542A760-1AB5-4981-8D20-F45BBCC71549Q38152980-E5BFC53F-6D51-400E-865B-A2359457D81BQ38201231-91E82CB6-45CB-4246-B292-F2F6D447B3A7Q38230880-8ACC9DDA-30F4-4E83-B838-8D0D5A3C02FBQ38485334-48AE52C0-3E77-4C5E-9023-8927A993168AQ38685359-66AA276E-EA16-4CC0-A5BF-1DFA8DF403B1Q38714687-DE0FA133-65E7-4039-ABAD-DC356076AE40Q38817090-0565A204-F66A-49D7-B257-DE36B215088DQ38845590-45A7A82C-A860-4579-AD5E-BDC84F41F692Q38874291-70D36094-E1DE-4A95-A547-C7A810E4D908Q38889427-CF9C1560-81D5-4054-8BCB-B58CDF1B9D8EQ38996724-2C1148FD-FF09-4DD8-BEF5-5F9EB7FFC25BQ39148281-3B55C7DC-38E0-4DE5-A6D4-43D31A0E39DBQ39233053-F3A91615-0756-4D2C-87F1-4EA98B7BA058Q41392046-68A4892C-C6DB-42D0-A93C-743B9A3554C7Q42639678-5321995A-E51C-42D9-B851-73C314D5B133
P2860
The role of B7 family molecules in hematologic malignancy
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
The role of B7 family molecules in hematologic malignancy
@ast
The role of B7 family molecules in hematologic malignancy
@en
type
label
The role of B7 family molecules in hematologic malignancy
@ast
The role of B7 family molecules in hematologic malignancy
@en
prefLabel
The role of B7 family molecules in hematologic malignancy
@ast
The role of B7 family molecules in hematologic malignancy
@en
P2860
P1433
P1476
The role of B7 family molecules in hematologic malignancy
@en
P2093
John G Gribben
P2860
P304
P356
10.1182/BLOOD-2012-10-385591
P407
P50
P577
2012-12-06T00:00:00Z